25C-NBF
25C-NBF
25C-NBF is a synthetic psychedelic compound that belongs to the NBOMe class of drugs. It is a derivative of the phenethylamine 2C-C, modified with a 2-methoxybenzyl (NB) group. This compound is known for its potent agonistic activity at the 5-HT2A receptor, which is primarily responsible for its psychedelic effects.
Chemical Structure and Properties
25C-NBF is chemically similar to other compounds in the NBOMe series, such as 25I-NBOMe and 25B-NBOMe. The "NBF" in its name indicates the presence of a 4-fluoro-2-methoxybenzyl group attached to the nitrogen atom of the phenethylamine backbone. This modification enhances its binding affinity to the 5-HT2A receptor, making it a highly potent psychedelic.
Pharmacology
The primary mechanism of action for 25C-NBF is its role as a partial agonist at the 5-HT2A receptor. This receptor is a subtype of the serotonin receptor family and is heavily implicated in the modulation of mood, perception, and cognition. Activation of the 5-HT2A receptor by 25C-NBF leads to the characteristic psychedelic effects, which can include altered visual and auditory perceptions, changes in thought patterns, and an altered sense of time.
Effects and Usage
The effects of 25C-NBF are similar to those of other psychedelics, such as LSD and psilocybin. Users may experience visual hallucinations, synesthesia, and profound changes in consciousness. Due to its potency, 25C-NBF is typically active at very low doses, often in the microgram range. It is important to note that the use of 25C-NBF, like other NBOMe compounds, can be associated with significant risks, including vasoconstriction, hypertension, and potential neurotoxicity.
Legal Status
The legal status of 25C-NBF varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of accepted medical use. It is important for individuals to be aware of the legal implications of possessing or distributing 25C-NBF in their respective regions.
Related Compounds
Related Pages
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD